The National Institute for Occupational Safety and Health NIOSH. Section Navigation. Facebook Twitter LinkedIn Syndicate. Minus Related Pages. Photos courtesy of Sean P. First Aid Workers should take these steps if a snake bites them: Seek medical attention as soon as possible dial or call local Emergency Medical Services [EMS].

Antivenom is the treatment for serious snake envenomation. The sooner antivenom can be started, the sooner irreversible damage from venom can be stopped. Driving oneself to the hospital is not advised because people with snakebites can become dizzy or pass out.

Take a photograph of the snake from a safe distance if possible. Identifying the snake can help with treatment of the snakebite. Keep calm. Inform your supervisor. Australia was one of the first countries in the world to experiment with snake antivenoms, in , when Frank Tidswell commenced immunization of a former ambulance horse with tiger snake N.

scutatus venom. CSL Ltd is the sole manufacturer of antivenoms for human use in Australia. Australian antivenoms are amongst the best in the world, in terms of purity and adverse reaction rate. Identification of the offending snake will aid in the choice of the appropriate antivenom and alert clinicians to particular features characteristic of envenomation by that type of snake.

Identification of snakes by the general public or by hospital staff is frequently unreliable. Sometimes, the snake is not seen, or is only glimpsed in retreat.

In these cases, a snakebite venom detection kit may be used. CSL Snake Venom Detection Kit including contents and packaging. Australia is the only country in the world that has snake venom detection kits.

They consist of a rapid two step enzyme immunoassay in which wells are coated with antibodies to the various snake venoms. A swab from the bite site, blood, or urine helps to select the type of snake antivenom which may have to be used.

Note that the primary purpose of the venom detection kit is not to decide whether envenomation has occurred i. The camels will create VHH antibodies against those specific venom toxins. The researchers plan to identify the best B cells and clone those antibody-encoding genes into bacteria to scale up their VHH antibody production.

While this research is still in progress, the data the team have collected so far look very strong, Harrison said. The best new treatment in the fight against snakebite might not actually be an antibody-based therapy at all, but a small molecule one.

Similar to camelid antibodies, small molecule drugs have the advantage of working quickly in the body and being relatively inexpensive to produce.

With their quick mechanisms of action, small molecule-based antivenoms may be good solutions for treating people who live in rural areas soon after they get bitten.

Unlike antibodies, which target and neutralize a specific protein, small molecules can take out entire toxin families.

This would potentially allow for a much broader neutralization of related snake venoms. Casewell and his team demonstrated this very possibility in a recent Nature Communications paper where they showed that by combining two small molecule toxin inhibitors, they could protect mice against venom from vipers in Central America, Asia, and Africa 5.

One of the drugs, marimastat, is a matrix metalloproteinase inhibitor that was originally tested in clinical trials for cancer treatment. The other is varespladib, a phospholipase A2 inhibitor, which is undergoing testing for anti-inflammatory disorders.

By testing small molecules that have already passed Phase 1 or 2 clinical trials for other indications, Casewell and his team hope that any small molecule drugs that neutralize venom toxins effectively they find will be easier to bring to market and eventually to patients than new antibody-based antivenoms may be.

He and his team recently demonstrated that the phase 1 approved metal chelator, 2,3-dimercaptopropanesulfonic acid DMPS neutralizes a variety of viper venoms 6 and the venom from the Dispholidus typus snake species, a venomous member of the colubrid snake family 7.

In fact, Casewell is now working with collaborators on a phase 1 clinical trial testing the safety of DMPS for snakebite in humans. If there are no adverse reactions in the healthy Kenyan volunteers in the phase 1 study, Casewell and his team plan to move the drug into a small-scale phase 2 study to test its effectiveness at treating snakebite victims.

For Harrison, who often collaborates with Casewell, small molecule drugs have exciting potential as cheap, safe, effective, and easy-to-manufacture antivenoms. While new antibody therapies and small molecule drugs are on the horizon, snakebite victims are still in need of safe and effective therapeutics right now.

Because the pace of bringing drugs to market can be slow, especially for a tropical neglected disease like snakebite, José María Gutiérrez, an emeritus snakebite and antivenom researcher at Instituto Clodomiro Picado, expects that animal-derived antibodies will still be the main snakebite treatment for many years to come.

Although many researchers like to say that animal-based antibody therapy is an old process, Gutiérrez pointed out that the technology has improved immensely over the years, cutting down the number of side effects snakebite patients experience.

As new antivenom strategies are tested, scientists like Gutiérrez and Casewell are working to improve existing antibody treatments for snakebite. The researchers mixed viper antivenoms in combinations of seven or twelve different antivenoms, and surprisingly, they found that the mixture of seven antivenoms protected against viper venom better than the mixture of twelve antivenoms 8.

But I think conceptually, there's something there that could be beneficial. But improved treatments alone will not be enough. To this end, the World Health Organization and snakebite researchers are working to help strengthen public health systems in countries where snakebite is endemic, to forge alliances with foundations and philanthropic organizations to provide financial support, and to engage with communities directly affected by snakebite.

Studies have shown that providing education around snakes and snakebite treatment to local communities and supplying transportation to hospital facilities reduces death due to snakebite in Nepal and India Habib performed a similar study in rural communities in Nigeria.

He and his team provided some communities with no intervention, education about snakebites, or education and an ambulance to shorten travel time to a hospital. He is working with his collaborators at the Liverpool School of Tropical Medicine to analyze the data, but he expects that the outcomes will be similar to prior studies demonstrating that community support improved snakebite outcomes.

Andreas Laustsen develops fully human recombinant antibodies as a safer and more effective treatment for snakebite compared to traditional animal-derived antivenoms.

Traditional antivenoms are made by immunizing animals like horses with snake venom. The animal produces antibodies against the individual toxins found in snake venom.

These animal-derived antibodies can be used to treat humans bitten by snakes, but because they come from animals, the human immune system can react to these as foreign proteins.

In response to the introduction of the venom a foreign substance , the animal produces antibodies to the venom. When the doses being injected are large, the amount of antibody produced is large. These antibodies are harvested by taking blood from the animals and separating out the antibodies, which are then fragmented and purified by a series of digestion and processing steps.

When injected into a patient, the binding sites on the antibody fragments bind to the venoms or venom components in the circulation and neutralize the activity of the venoms in the patient.

Antivenoms have been made since the s. Australia was one of the first countries in the world to experiment with snake antivenoms, in , when Frank Tidswell commenced immunization of a former ambulance horse with tiger snake N.

scutatus venom. CSL Ltd is the sole manufacturer of antivenoms for human use in Australia. Australian antivenoms are amongst the best in the world, in terms of purity and adverse reaction rate.

Identification of the offending snake will aid in the choice of the appropriate antivenom and alert clinicians to particular features characteristic of envenomation by that type of snake.

Identification of snakes by the general public or by hospital staff is frequently unreliable. Sometimes, the snake is not seen, or is only glimpsed in retreat. In these cases, a snakebite venom detection kit may be used. Location of care Uncomplicated snakebites can be managed at a regional centre as long as the following resources are available:.

First aid Apply a broad pressure immobilisation bandage,. Immobilise the joints either side of the bite site use a splint , Immobilise the entire child as well lay the child down. DO NOT remove the bandage until in a centre with full treatment facilities, as discussed above.

Serial blood tests and clinical examinations take a minimum of 12 hours after the time of the bite; these can occur in Emergency Departments or with inpatient units depending on local experience and level of comfort. All children with evidence of envenomation should be admitted to hospital refer to Location of care information in treatment section above.

In complicated snakebites or where the above resources are not available to manage snakebite, the child should be transferred to a tertiary paediatric centre.

For emergency advice and paediatric or neonatal ICU transfers, call the Paediatric Infant Perinatal Emergency Retrieval PIPER Service: Children with suspected snakebite should only be discharged in daylight hours neurological signs can be subtle and only evident when children are awake.

If antivenom was administered, ensure that the family is given advice on how to recognise serum sickness:. Snakebite — SCV patient fact sheet.

Children undergoing serial testing are suitable for both the ED Short Stay ward and the Short Stay Unit. Envenomed children should be considered for PICU admission but may be suitable for a ward General Medical admission depending on clinical signs and degree of coagulopathy.

The Monash Health clinical toxicologist on-call should be consulted in all cases of suspected snakebite. Children undergoing serial bloods tests are suitable for either ED Short Stay or ward admission, depending on site.

Children who have received anti-venom may be suitable for a toxicology, inpatient or PICU Clayton admission depending on age and clinical features.

Stay informed with the latest updates on coronavirus COVID The Royal Children's Hospital Melbourne. Health Professionals Patients and Families Departments and Services Research Health Professionals Departments and Services Patients and Families Research Home About News Careers Support us Contact.

Clinical Practice Guidelines Toggle section navigation In this section About Clinical Practice Guidelines CPG index Nursing Guidelines Paediatric Improvement Collaborative Parent resources Retrieval services CPG Committee Calendar CPG information Other resources CPG feedback.

In this section About Clinical Practice Guidelines CPG index Nursing Guidelines Paediatric Improvement Collaborative Parent resources Retrieval services CPG Committee Calendar CPG information Other resources CPG feedback.

This guideline has been adapted for statewide use with the support of the Victorian Paediatric Clinical Network. This should particularly occur with envenomation by snakes of snake-handlers or other sources of exotic snakes, as well as by those bitten by snakes in locations other than Victoria or Tasmania.

In Victoria, there are 3 venomous snakes — Brown, Tiger and Red-Bellied Black. Antivenom should be administered early if signs of envenomation. Brown and tiger antivenom will cover all Victorian snakes.

For 24 hour advice, contact Victorian Poisons Information Centre 13 11 26 Background Snake bite is uncommon in Victoria and envenomation systemic poisoning from the bite is rare. There are no sea snakes in Victoria, however land-based snakes can swim.

Assessment Focus on evidence of envenomation. Once the possibility of snakebite has been raised, it is important to determine whether a child has been envenomed to establish the need for antivenom.

Do not try to suck out the venom. Do not apply ice or immerse the wound in water. Do not drink alcohol as a painkiller. Do not take pain relievers such as aspirin, ibuprofen, naproxen. Do not apply electric shock or folk therapies.

Page last reviewed: June 28, Content source: National Institute for Occupational Safety and Health. home Workplace Safety and Health Topics. Hazards to Outdoor Workers. Related Topics Protective Clothing Skin Exposures and Effects.

Follow NIOSH Facebook Pinterest Twitter YouTube. Links with this icon indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention CDC cannot attest to the accuracy of a non-federal website.

Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.